Maze Therapeutics

Update in progress

MAZE (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Maze Therapeutics is a clinical-stage biopharmaceutical company in South San Francisco that develops small-molecule precision medicines for kidney and metabolic diseases. Its lead programs include MZE829, an oral APOL1 inhibitor in Phase II for APOL1-associated kidney disease; MZE782, an oral inhibitor for phenylketonuria and chronic kidney disease in Phase II-ready trials; and MZE001 for Pompe disease. It collaborates with Trace Neuroscience, Shionogi, and Neurocrine Biosciences.

Company score

Sentiment: 0.29; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.18; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.03; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.16; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive